MTPC filed a Japanese New Drug Application for vadadustat in July 2019. Akebia shares rights to vadadustat with Otsuka and Mitsubishi Tanabe Pharma. Vadadustat is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority with the exception of Japan's Ministry of Health, Labour and Welfare (MHLW). Within Japan, Vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and … The drug is already under review in Japan. Vadadustat is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority with the exception of Japan’s Ministry of Health, Labour and Welfare (MHLW). A Conversation With A Nephrologist To Understand The Chances Of Approval And Market Potential Of FGEN's Roxadustat And AKBA's Vadadustat For Anemia In … The PRO2TECT trial data are expected in mid-2020. In Japan, vadadustat is approved as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients. Vadadustat is an investigational therapy and is not approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority. The collaboration provides capital for the global development program for vadadustat, and commercial resources for a U.S. launch of vadadustat upon approval by the Food and Drug Administration. Apart from Amgen’s Epogen and … This article summarizes the milestones in the development of vadadustat leading to this first approval. The company plans to file approval applications in the U.S. and Europe "as quickly as possible" pending positive results, CEO John Butler said in a statement. Akebia Therapeutics Inc. recently announced that Japan has approved vadadustat for the treatment of anemia due to chronic kidney disease. Vadadustat is in global Phase 3 development for the treatment of anemia due to CKD and is not approved by the U.S. Food and Drug Administration (FDA) or … We note that vadadustat may face competition upon potential approval from the already approved drugs for anemia in CKD patients. Vadadustat is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any regulatory authority for use outside of Japan. Vadadustat is in global Phase 3 development for the treatment of anemia due to CKD and is not approved by the U.S. Food and Drug Administration (FDA) or … About Mitsubishi Tanabe Pharma The drug is approved in Japan for use in adult patients with anaemia associated with CKD and regulatory submissions are planned in the USA and the EU.